MASTERINVEST Kapitalanlage GmbH Makes New Investment in Pfizer Inc. $PFE

MASTERINVEST Kapitalanlage GmbH bought a new stake in shares of Pfizer Inc. (NYSE:PFE) in the 2nd quarter, Holdings Channel reports. The firm bought 47,996 shares of the biopharmaceutical company’s stock, valued at approximately $1,163,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of PFE. Westbourne Investments Inc. purchased a new position in Pfizer in the 1st quarter worth about $2,411,000. Bourne Lent Asset Management Inc. grew its stake in Pfizer by 90.8% in the 2nd quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock worth $927,000 after acquiring an additional 18,200 shares in the last quarter. Ossiam increased its position in shares of Pfizer by 71.2% during the second quarter. Ossiam now owns 5,650,573 shares of the biopharmaceutical company’s stock worth $136,970,000 after acquiring an additional 2,349,058 shares during the period. Strs Ohio bought a new stake in shares of Pfizer during the first quarter valued at approximately $49,968,000. Finally, IFM Investors Pty Ltd boosted its holdings in shares of Pfizer by 3.8% in the second quarter. IFM Investors Pty Ltd now owns 1,127,143 shares of the biopharmaceutical company’s stock valued at $27,322,000 after purchasing an additional 41,263 shares during the period. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Price Performance

PFE opened at $25.86 on Monday. The firm has a market capitalization of $147.04 billion, a PE ratio of 15.04 and a beta of 0.46. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The business’s 50-day moving average is $25.12 and its two-hundred day moving average is $24.78. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. The business had revenue of $16.65 billion for the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. Pfizer’s dividend payout ratio is presently 100.00%.

Analyst Ratings Changes

PFE has been the topic of several research reports. Scotiabank started coverage on Pfizer in a report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price objective on the stock. Sanford C. Bernstein restated a “market perform” rating and set a $30.00 price target on shares of Pfizer in a research note on Friday, October 31st. Bank of America upped their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. The Goldman Sachs Group reiterated a “neutral” rating and set a $26.00 target price on shares of Pfizer in a report on Wednesday, November 5th. Finally, BMO Capital Markets restated an “outperform” rating on shares of Pfizer in a report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Pfizer has an average rating of “Hold” and a consensus target price of $28.33.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.